Is Your Anti-Ageing Stack Actually Working? (The 2026 Reality Check)

Author: Rohan Smith | Functional Medicine Practitioner | Adelaide, SA

Quick Answer

Longevity is defined as the length of life, but in healthcare, it usually refers to healthspan: the years you can live with good function, independence, and low disease burden. An effective anti-ageing stack can play a key role in supporting healthspan by targeting key factors that influence aging.

The core mechanism behind most evidence-based “longevity” strategies is consistent across studies: they reduce major drivers of early disability and mortality—especially cardiometabolic disease risk (blood pressure, glucose regulation, atherogenic lipoproteins), loss of muscle and bone, and sleep/circadian disruption—by improving underlying physiology over time. [1–6]

2026 reality check: the best-supported longevity tools are still “boring but powerful” (exercise, sleep regularity, cardiometabolic risk optimisation). What has not changed is that many “anti-ageing stacks” and off-label drugs remain experimental for healthspan outcomes in the general population and may carry meaningful risks without appropriate monitoring. [2,5,6,13–18]

Testing or targeted intervention may be considered when you have strong family history (early heart disease, diabetes, dementia), persistent symptoms (fatigue, poor recovery, sleep disruption), or unfavourable trends in markers like blood pressure, HbA1c, triglycerides, hs-CRP, or unexplained changes in waist circumference or strength. [2,5,6]

Core Concept

Many longevity claims fail because they confuse biomarkers (a number that changes) with outcomes (fewer heart attacks, strokes, fractures, disability, and deaths). A practical evidence hierarchy looks like this:

• Most supported (low risk, high upside): resistance training + aerobic activity, sleep regularity, and not smoking—because they reliably improve risk factors and functional capacity linked to long-term outcomes. [1–4]
• Supported in the right context: Mediterranean-style dietary patterns (especially in higher-risk groups) and evidence-based medical management of blood pressure and lipids when indicated. [2,5,6,12]
• Mixed evidence / context-dependent risk: omega-3 supplementation (potential CV benefit in meta-analyses, but atrial fibrillation risk signal—especially at higher doses). [9–11]
• Insufficient evidence or higher risk for “longevity use”: off-label “geroprotective” drugs (e.g., rapamycin/rapalogs; metformin in non-diabetic people) outside clinical trials; many NAD+ booster regimens beyond short-term biomarker shifts. [13–20]

This evidence hierarchy differs from the canonical 12 hallmarks of ageing (updated 2023), which include genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis—many of which overlap with the cardiometabolic and functional decline pathways addressed here.

Solution/Test

Think of longevity as a systems audit. The goal is to identify your highest-leverage constraints and address them in a sustainable way.

1. The “Big 5” longevity metrics (practical and trackable)
   • Blood pressure trend: Home averages matter. In higher-risk adults, intensive BP lowering reduced major cardiovascular events and mortality in large RCT data, but can increase some adverse events—so targets should be individualised. [5,6]
   • Glycaemic regulation: fasting glucose and HbA1c (and sometimes fasting insulin) help assess insulin resistance risk, which is strongly linked to cardiovascular and cognitive outcomes. (Interpretation depends on context and medications.)
   • Lipid pattern: apoB/non-HDL/LDL patterns and triglycerides provide a clearer “atherogenic burden” picture. Statin RCT meta-analyses show event reduction across ages, with more nuance around primary prevention decisions in older adults—shared decision-making matters. [12,13]
   • Body composition and strength: preserving muscle supports metabolic resilience and reduces frailty risk; resistance training is one of the most consistent healthspan tools. [1,21]
   • Sleep duration and regularity: short and long sleep duration are associated with higher mortality risk in meta-analyses; regularity and sleep quality also matter clinically. [3,4]
2. Food pattern that best matches outcomes
   A Mediterranean dietary pattern has RCT evidence for reducing cardiovascular events in higher-risk groups. [2] In practice, it’s less about a label and more about repeatable principles: high-fibre plants, legumes, nuts, extra-virgin olive oil, adequate protein, and minimal ultra-processed foods.
3. Calorie restriction: promising, but not universally “safe”
   Two-year human calorie restriction trials show improvements in several cardiometabolic risk markers. [7,8] However, aggressive restriction can be problematic for some people (e.g., worsening sleep, reduced lean mass, or triggering disordered eating patterns). A safer “longevity version” for many is: mild energy deficit (if needed) + adequate protein + progressive resistance training. [7,8,21]
4. Supplements: what has signal, and what needs caution
   • Creatine monohydrate: meta-analytic evidence suggests improved strength-related outcomes when combined with resistance training in older adults; it’s generally well tolerated, but people with kidney disease or complex comorbidities should use clinician oversight. [21]
   • Omega-3 (EPA/DHA): meta-analyses suggest potential cardiovascular outcome benefits in some contexts, but RCT meta-analyses also show an increased atrial fibrillation risk—particularly at higher doses—so risk/benefit should be individualised (especially with arrhythmia history or relevant meds). [9–11]
   • Vitamin D: large meta-analyses show mixed results overall; benefits are most plausible and clinically common in deficiency. Routine high-dose vitamin D for “longevity” is not consistently supported. [12]
   • Resveratrol and many polyphenol extracts: meta-analyses show improvements in some surrogate vascular markers (e.g., endothelial function), but this is not the same as proven longevity benefit. [22]
   • NMN/NAD+ boosters: RCTs show NAD biomarkers can rise and short-term tolerability can be acceptable, but long-term healthspan outcomes and who benefits most remain unclear. [19]
5. “Longevity drugs”: plausible biology, incomplete outcomes
   mTOR inhibitors (rapamycin/rapalogs): mTOR pathway modulation is strongly linked to ageing biology in models, and human studies have explored immune-related endpoints with some promising signals. [14,15] However, using rapamycin off-label for “longevity” is not the same as treating an approved indication; safety and appropriate monitoring are highly individual and the general-population healthspan case is not settled. [18]
   Metformin: metformin is established for type 2 diabetes and has geroscience rationale, but whether it meaningfully extends lifespan/healthspan in non-diabetic people remains debated; reviews emphasise uncertainty and the need for robust outcomes data. [16,17]

When to Consider (and When to Avoid) “Longevity” Interventions

You may want a structured longevity plan if you:

• Have a strong family history of cardiometabolic disease or dementia
• Notice declining strength, balance, or recovery
• Have persistent fatigue, sleep disruption, or unexplained waist/weight changes
• Have rising BP, HbA1c/glucose, triglycerides, or inflammatory markers over time

You should be more cautious (and seek clinician oversight) if you:

• Are pregnant/breastfeeding, have kidney/liver disease, or take anticoagulants/antiarrhythmics (higher interaction/side-effect risk)
• Have a history of eating disorders (calorie restriction and aggressive tracking may be harmful)
• Are considering off-label prescription drugs for “anti-ageing” outside a research setting (risk/benefit is uncertain and monitoring needs are real) [16–18]

If your longevity focus overlaps with persistent low energy, consider our perspective on fatigue and healthy ageing.

Next Steps

1. Start with measurements, not stacks: home BP averages, waist circumference, weekly resistance training sessions, and sleep timing. [1,3,5]
2. Pick the highest-leverage habit pair: (a) strength training + protein adequacy, (b) sleep regularity + morning light exposure, or (c) Mediterranean pattern + ultra-processed reduction. [1–3,21]
3. Medical optimisation often outperforms supplement complexity: if BP, glucose, or lipids are trending the wrong way, discuss evidence-based options with your practitioner—this remains a major risk-reduction pathway. [5,6,12,13]
4. Use supplements as “gap fillers” only: consider creatine for strength support; omega-3 only with a clear rationale and dose safety; vitamin D based on measured status. [9–12,21]
5. Run single-variable experiments: change one input for 8–12 weeks, then reassess symptoms plus objective markers (avoids placebo-driven “stack creep”).

If you want a longevity plan that accounts for gut-driven inflammation and metabolic resilience, see gut microbiome and inflammation. If thyroid patterning is relevant to your energy, temperature tolerance, lipids, or weight trajectory, explore thyroid patterns and metabolic health. If stress/sleep rhythm appears central, clinician-guided testing may be discussed (when appropriate), including DUTCH Complete hormone testing or an Organic Acids Test (OAT)—used to inform patterns and decision-making, not as a stand-alone “longevity diagnosis.”

Key Insights

• Longevity is mostly risk management: the best-supported strategies reduce cardiometabolic risk and preserve function. [2,5,6,12,13]
• Strength is a healthspan biomarker you can train: muscle is metabolic reserve and independence insurance. [1,21]
• Supplements are secondary: a few can support training or correct deficiency, while others show mixed outcomes and sometimes meaningful risks. [9–12,19,21,22]
• Off-label “anti-ageing drugs” remain research territory: plausible mechanisms are not the same as proven population-level benefits. [16–18]

If you’re in Adelaide and want an evidence-based longevity plan that prioritises safety, measurable outcomes, and your unique history, you can book with Elemental Health and Nutrition (Rohan Smith, Functional Medicine Practitioner) via elementalhealthandnutrition.com.au.

1. Arem H, et al. Leisure time physical activity and mortality: a detailed pooled analysis of the dose-response relationship. JAMA Intern Med. 2015. https://pubmed.ncbi.nlm.nih.gov/25844730/
2. Estruch R, et al. Primary prevention of cardiovascular disease with a Mediterranean diet (PREDIMED). N Engl J Med. 2013. https://pubmed.ncbi.nlm.nih.gov/23432189/
3. Cappuccio FP, et al. Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. Sleep. 2010. https://pubmed.ncbi.nlm.nih.gov/20469800/
4. Caputo M, et al. Sleep duration and all-cause mortality: dose-response meta-analysis. 2025. https://pubmed.ncbi.nlm.nih.gov/40047115/
5. SPRINT Research Group; Wright JT Jr, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015. https://pubmed.ncbi.nlm.nih.gov/26551272/
6. Williamson JD, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years. JAMA. 2016. https://pubmed.ncbi.nlm.nih.gov/27195814/
7. Ravussin E, et al. A 2-Year Randomized Controlled Trial of Human Caloric Restriction: Feasibility and Effects on Predictors of Health Span and Longevity. J Gerontol A Biol Sci Med Sci. 2015. https://pubmed.ncbi.nlm.nih.gov/26187233/
8. Kraus WE, et al. 2 years of calorie restriction and cardiometabolic risk (CALERIE). 2019. https://pubmed.ncbi.nlm.nih.gov/31303390/
9. Khan SU, et al. Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis. 2021. https://pubmed.ncbi.nlm.nih.gov/34505026/
10. Bernasconi AA, et al. Effect of Omega-3 dosage on cardiovascular outcomes: a dose-response meta-analysis. 2021. https://pubmed.ncbi.nlm.nih.gov/32951855/
11. Gencer B, et al. Effect of long-term marine omega-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials. 2021. https://pubmed.ncbi.nlm.nih.gov/34612056/
12. Ruiz-García A, et al. Vitamin D supplementation and its impact on mortality and cardiovascular outcomes: systematic review and meta-analysis of 80 randomized clinical trials. Nutrients. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10146299/
13. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: an individual participant data meta-analysis of 28 randomized controlled trials. Lancet. 2019. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31942-1/fulltext
14. Nanna MG, et al. Primary Prevention Statin Therapy in Older Adults. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9830552/
15. Mannick JB, et al. mTOR inhibition improves immune function in the elderly. 2014. https://pubmed.ncbi.nlm.nih.gov/25540326/
16. Mannick JB, et al. Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomized trials. 2021. https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(21)00062-3/fulltext
17. Mohammed I, et al. A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8374068/
18. Barzilai N, et al. Metformin as a Tool to Target Aging. 2016. https://pmc.ncbi.nlm.nih.gov/articles/PMC5943638/
19. Roark KM, et al. Rapamycin for longevity: the pros, the cons, and future perspectives. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12226543/
20. Yi L, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized clinical trial. 2023. https://pubmed.ncbi.nlm.nih.gov/36482258/
21. Sharifian G, et al. Impact of creatine supplementation and exercise training in older adults: a systematic review and meta-analysis. 2025. https://pubmed.ncbi.nlm.nih.gov/41062952/
22. Mohammadipoor N, et al. Resveratrol supplementation and endothelial health: systematic review and meta-analysis of randomized controlled trials. 2022. https://pubmed.ncbi.nlm.nih.gov/35833325/